The combined company’s pipeline features eight oncolytic virotherapies in clinical development, seven in late-stage preclinical development and validated oncolytic virotherapy platforms. The merger consolidates two oncolytic platforms, an
The drug is a ready-to-use version of The Medicines Co’s blood clot preventer Angiomax, which should also to be taken with aspirin. It is intended for use as
In the Octave Induction 1 and Octave Induction 2 studies, tofacitinib reduced symptoms of moderate to severe UC and induced remission of the disease. In one study, 18.5%
Under a phase 1b/2 study, Kite’s investigational anti-CD19 Chimeric Antigen Receptor (CAR) T cell product, KTE-C19, will be evaluated with Genentech’s investigational anti-PDL1 antibody atezolizumab. The study, which
The primary endpoint of the study demonstrated that the Advair Diskus-combination (FSC) twice-daily showed non-inferiority compared to corresponding doses of fluticasone propionate (FP) twice-daily on the risk of
Kovaltry is an unmodified full-length recombinant factor VIII product, which is designed to reduce bleeding in patients with hemophilia A when administered prophylactically two or three times a
The partnership will unite GSK’s cell and gene therapy based treatment developments with Miltenyi Biotec’s cell processing and related technologies. The companies aim to identify new ways to
Patients taking a 350 mg dose of the drug demonstrated a 24% reduction, while patients who took the 700 mg dose showed a 30% reduction compared to a
After completion of the acquisition, including the agreed upon transition period, Orexigen will hold all rights to Contrave in almost all territories globally. The companies have agreed to
The approval was based on its bioequivalence to the standard melphalan formulation (Alkeran) in a phase 2 clinical study. Evomela has been granted Orphan Drug Designation by the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.